Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma - Moderna

Unsure

news.modernatx.comby mostly nonSubmitted September 4, 2026

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With...

The Verdict

ClassificationUnsure

ConfidenceHigh confidence

Analyzedtext

Community Verdict

Be the first to vote on this assessment.

Embed Badge

Add this badge to your site to show the AI classification for this content.

[![Real Press](https://real.press/api/badge/7380d811-da08-41a1-8e32-d2d118b77da4)](https://real.press/content/7380d811-da08-41a1-8e32-d2d118b77da4)